AR115790A1 - Apirasas solubilizadas, métodos y usos - Google Patents
Apirasas solubilizadas, métodos y usosInfo
- Publication number
- AR115790A1 AR115790A1 ARP190102009A ARP190102009A AR115790A1 AR 115790 A1 AR115790 A1 AR 115790A1 AR P190102009 A ARP190102009 A AR P190102009A AR P190102009 A ARP190102009 A AR P190102009A AR 115790 A1 AR115790 A1 AR 115790A1
- Authority
- AR
- Argentina
- Prior art keywords
- solubilized
- methods
- apirases
- concerned
- preventing
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102000007347 Apyrase Human genes 0.000 abstract 1
- 108010007730 Apyrase Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
- C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
- C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente se refiere al diseño y uso terapéutico de polipéptidos de apirasa solubilizados, composiciones farmacéuticas, usos terapéuticos y métodos útiles para prevenir y tratar el daño tisular.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18184269 | 2018-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115790A1 true AR115790A1 (es) | 2021-02-24 |
Family
ID=62985993
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102009A AR115790A1 (es) | 2018-07-18 | 2019-07-16 | Apirasas solubilizadas, métodos y usos |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220356455A1 (es) |
| EP (1) | EP3824079A1 (es) |
| JP (2) | JP7425784B2 (es) |
| KR (1) | KR20210035806A (es) |
| CN (1) | CN112424346B (es) |
| AR (1) | AR115790A1 (es) |
| AU (1) | AU2019306821B2 (es) |
| BR (1) | BR112021000586A2 (es) |
| CA (1) | CA3103684A1 (es) |
| CL (1) | CL2021000129A1 (es) |
| CO (1) | CO2021000210A2 (es) |
| CR (1) | CR20210021A (es) |
| CU (1) | CU20210008A7 (es) |
| EA (1) | EA202190057A1 (es) |
| EC (1) | ECSP21002804A (es) |
| IL (1) | IL280191A (es) |
| JO (1) | JOP20210008A1 (es) |
| MA (1) | MA53177A (es) |
| MX (1) | MX2021000542A (es) |
| PE (1) | PE20210185A1 (es) |
| PH (1) | PH12021550122A1 (es) |
| SG (1) | SG11202011776RA (es) |
| UY (1) | UY38299A (es) |
| WO (1) | WO2020016804A1 (es) |
| ZA (1) | ZA202007187B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021243173A1 (en) * | 2020-05-28 | 2021-12-02 | Charm Sciences, Inc. | Methods and assemblies for sample analysis |
| TW202404627A (zh) | 2022-07-29 | 2024-02-01 | 瑞士商諾華公司 | 使用cd39、重組cd39用於急性器官損傷的治療 |
| WO2024023746A1 (en) | 2022-07-29 | 2024-02-01 | Novartis Ag | Improved production of cd39 variants |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023459A1 (en) | 1998-10-16 | 2000-04-27 | Immunex Corporation | Inhibitors of platelet activation and recruitment |
| US20020002277A1 (en) * | 1998-10-16 | 2002-01-03 | Maliszewski Charles Richard | Inhibitors of platelet activation and recruitment |
| US6867177B2 (en) | 1999-08-13 | 2005-03-15 | The Trustees Of Columbia University In The City Of New York | CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders |
| US7247300B1 (en) | 2002-11-07 | 2007-07-24 | Apt Therapeutics, Inc. | Therapeutic use of soluble CD39L3 |
| EP1861498A4 (en) | 2005-03-17 | 2009-06-24 | Ca Nat Research Council | EXPRESSION VECTORS FOR TRANSIENT GENETIC EXPRESSION AND MAMMALIAN CELLS EXPRESSING THE SAME |
| US8535662B2 (en) * | 2010-01-13 | 2013-09-17 | Apt Therapeutics, Inc. | Apyrase therapy for bleeding conditions |
| KR102288857B1 (ko) | 2013-12-20 | 2021-08-11 | 노파르티스 아게 | 신규한 진핵 세포 및 관심 생성물의 재조합 발현 방법 |
| DK3083677T3 (da) | 2013-12-20 | 2019-11-25 | Novartis Ag | Hidtil ukendte eukaryote celler og fremgangsmåder til rekombinant ekspression af et produkt af interesse |
-
2019
- 2019-07-15 UY UY0001038299A patent/UY38299A/es unknown
- 2019-07-16 AR ARP190102009A patent/AR115790A1/es unknown
- 2019-07-17 BR BR112021000586-2A patent/BR112021000586A2/pt unknown
- 2019-07-17 CN CN201980047594.2A patent/CN112424346B/zh active Active
- 2019-07-17 CA CA3103684A patent/CA3103684A1/en active Pending
- 2019-07-17 EA EA202190057A patent/EA202190057A1/ru unknown
- 2019-07-17 MX MX2021000542A patent/MX2021000542A/es unknown
- 2019-07-17 KR KR1020217001187A patent/KR20210035806A/ko unknown
- 2019-07-17 PE PE2021000054A patent/PE20210185A1/es unknown
- 2019-07-17 MA MA053177A patent/MA53177A/fr unknown
- 2019-07-17 SG SG11202011776RA patent/SG11202011776RA/en unknown
- 2019-07-17 WO PCT/IB2019/056117 patent/WO2020016804A1/en active Application Filing
- 2019-07-17 CR CR20210021A patent/CR20210021A/es unknown
- 2019-07-17 US US17/261,533 patent/US20220356455A1/en active Pending
- 2019-07-17 CU CU2021000008A patent/CU20210008A7/es unknown
- 2019-07-17 JO JOP/2021/0008A patent/JOP20210008A1/ar unknown
- 2019-07-17 EP EP19769879.8A patent/EP3824079A1/en active Pending
- 2019-07-17 AU AU2019306821A patent/AU2019306821B2/en active Active
- 2019-07-17 JP JP2021502432A patent/JP7425784B2/ja active Active
-
2020
- 2020-11-18 ZA ZA2020/07187A patent/ZA202007187B/en unknown
-
2021
- 2021-01-14 CO CONC2021/0000210A patent/CO2021000210A2/es unknown
- 2021-01-14 EC ECSENADI20212804A patent/ECSP21002804A/es unknown
- 2021-01-14 IL IL280191A patent/IL280191A/en unknown
- 2021-01-15 CL CL2021000129A patent/CL2021000129A1/es unknown
- 2021-01-15 PH PH12021550122A patent/PH12021550122A1/en unknown
-
2023
- 2023-11-14 JP JP2023193640A patent/JP2024023297A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3103684A1 (en) | 2020-01-23 |
| MA53177A (fr) | 2021-05-26 |
| CL2021000129A1 (es) | 2021-08-20 |
| ZA202007187B (en) | 2022-06-29 |
| WO2020016804A1 (en) | 2020-01-23 |
| KR20210035806A (ko) | 2021-04-01 |
| US20220356455A1 (en) | 2022-11-10 |
| IL280191A (en) | 2021-03-01 |
| PE20210185A1 (es) | 2021-02-02 |
| EP3824079A1 (en) | 2021-05-26 |
| UY38299A (es) | 2020-02-28 |
| CU20210008A7 (es) | 2021-08-06 |
| SG11202011776RA (en) | 2021-02-25 |
| TW202016299A (zh) | 2020-05-01 |
| CR20210021A (es) | 2021-03-23 |
| MX2021000542A (es) | 2021-03-29 |
| JP7425784B2 (ja) | 2024-01-31 |
| CN112424346B (zh) | 2024-08-06 |
| CN112424346A (zh) | 2021-02-26 |
| EA202190057A1 (ru) | 2021-08-24 |
| JP2024023297A (ja) | 2024-02-21 |
| JOP20210008A1 (ar) | 2021-01-12 |
| PH12021550122A1 (en) | 2021-09-27 |
| AU2019306821B2 (en) | 2022-09-29 |
| CO2021000210A2 (es) | 2021-01-18 |
| AU2019306821A1 (en) | 2020-12-24 |
| BR112021000586A2 (pt) | 2021-04-06 |
| ECSP21002804A (es) | 2021-04-29 |
| JP2021529550A (ja) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000180A (es) | INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS | |
| CL2019003636A1 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson. | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
| UY37480A (es) | Nuevos derivados de quinolina | |
| CL2020001797A1 (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas. | |
| CL2021000129A1 (es) | Apirasas solubilizadas, métodos y usos | |
| CL2019003892A1 (es) | Nuevos derivados de azaquinolina. | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| DOP2019000275A (es) | Nuevos derivados de pirazol bicíclicos | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| CL2018001913A1 (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| CO2018008449A2 (es) | Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| CL2016002482A1 (es) | Compuestos de azol sustituidos con amida como inhibidores de tnks1 y/o tnks2. | |
| AR120057A1 (es) | Composiciones neoantigénicas y usos de estas | |
| CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al | |
| CL2018001911A1 (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano | |
| CO2018012180A2 (es) | Métodos de tratamiento para enfermedades colestásicas y fibróticas | |
| CL2020001062A1 (es) | Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos. | |
| CL2021000529A1 (es) | Administración prolongada de lasmiditan por la noche para la prevención de la migraña | |
| CL2021000580A1 (es) | Uso de inhibidores de la caseina quinasa 1 para el tratamiento de enfermedades vasculares. | |
| BR112018003455A2 (pt) | composição ou composição farmacêutica e uso da composição | |
| CL2020000221A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| CL2019002480A1 (es) | Derivados de pirazol como inhibidores de bromodominio. |